Ceryx /ˈsiriks/ ubiquitous, trusted heralds acting as inviolable messengers.
Privately owned Oxford Nanopore offers a range of tools and and instruments based on a proprietary nanopore-based DNA and RNA sequencing technology.
The companies will use Natera's Signatera circulating tumor DNA assay to assess response to NEO-PV-01, a clinical trial-stage neoantigen cancer vaccine.
The test is designed to detect cancer-driver gene variants associated with certain targeted solid tumor therapies, and is validated as a companion diagnostic.
Roche Diagnostics' revenues were driven by its centralized and point-of-care solutions as well as its tissue diagnostics business, both rising in the high-single digits.
BioCeryx is a molecular diagnostic company on a mission to liberate precision medicine - which it does with unique tech that delivers advanced.
Seven years ago, in October 2011, Sequenom launched their Noninvasive Prenatal Test for Down Syndrome . NIPT (aka NIPS) promised a safe and highly accurate way to screen for Down Syndrome. The first NIPT, MarterniT21, was indicated for women at high...
Interesting population based study using NIPT samples, but where is the clinical utility beyond prenatal Dx?
• A BGI team demonstrated that it is possible to profile population genetics, viral infection patterns, and more using NIPT
• 70% of the 10 million NIPT test performed so far have been done in China
• this opens up new avenues for investigating hypotheses regarding interactions between viruses and host DNA genetic variability
The company plans to use parts of the proceeds from the offering to pay for the recent settlement with Illumina.
We came across an interesting report by Frost & Sullivan from September 2017 titled “ Precision Medicine- Growth Opportunities for Genomics Technologies”. It summarized some of the expected growth opportunities in Companion Diagnostics (CDx), NGS,...
Centogene will collect dried blood spot samples and perform genetic analysis to find and recruit Parkinson's disease patients for Denali's LRRK2 inhibitor trials.
Expands portfolio with three new kitted transplant products launching in 2019. Delivers new insights into the clinical Transplantome by.
We wanted to highlight the recent article “ Dx Companies See Rise in Demand for Integrated Clinical Chemistry, Immunoassay Systems for Central Labs ”. The bottom line of the article is “In response to economic and operational pressures, testing is...
Exactly two years ago a policy statement was published, which reviewed the basic principles governing the adoption of genomic testing services [i] . The paper concluded that although the cost and time required to perform NGS was decreasing, there...
Many leaders struggle with balancing their focus on achieving results and creating a positive culture. An interesting article in HBR provides some insight into what strategy is most effective : if a leader is seen as strongly focusing on achieving...
In a bid to expand in the field of fertility diagnostics, Quest Diagnostics DGX recently acquired ReproSource, a provider of specialty fertility.
Read time: 3 minutes, 8 seconds It won’t be news to anybody to say that most of the technologies that are tagged as “disruptive”… are simply not. So what is disruptive innovation? According to Clayton Christensen , who developed the theory of...
The technology works directly from clinical samples and can potentially be multiplexed to detect tens of targets, according to the firm.
Researchers have been developing nanopore metagenomic sequencing protocols to enable real-time outbreak surveillance outside the traditional laboratory.
Premaitha Licenses NIPT Tech From Illumina Under Settlement https://t.co/gDxn26MaDd
Congrats @Qiagen and @neumodx for the merger. Qiagen, NeuMoDx Ink Partnership, Merger Agreement https://t.co/R47dqyLOhe
The agreements involve the commercialization of the NeuMoDx 288 and 96 platforms for fully integrated, sample-to-answer, PCR-based molecular diagnostic testing.
An often overlooked trend in the diagnostics industry: the silent wave of sample-to-answer platform acquisitions. Read our take on this and let us know what you think. https://t.co/esf3VpEG5s
Reuters reports that Roche (OTCQX:RHHBY +0.4%) is stepping up its cost-cutting efforts aimed at dampening the effect of looming biosimilars. CEO Severin Schwan believes the company can fill the sales
Sobering op-ed in the NYT. Us working in Precision Medicine must remain humble and keep working for patients. "Are We Being Misled About Precision Medicine?" https://t.co/1MpeoYYud9
Doctors and hospitals love to talk about the cancer patients they’ve saved, and reporters love to write about them. But deaths still vastly outnumber the rare successes.
Microarray for POC: Novacyt, Applied Microarrays Partner on SNP Assay Development https://t.co/V983LvNjph
Bristol-Myers Squibb to Use Natera's Cell-Free DNA Assay in Immunotherapy Study https://t.co/29d1y8IvEm
Under the deal, Novacyt's Primerdesign business will work with Applied Microarrays on the development of microarray-based diagnostic assays.
The pharma company plans to use the Signatera assay to determine whether it can identify patients who will respond to immunotherapy.
Great recommendations for any development team in biotech: understand your three categories of risk, how they distributed, and how to derisk by transforming beliefs into knowledge
Risk: A User’s Guide For Drug Developers https://t.co/xSNK1l99mk
In my last post, I argued that the key to the success – and perhaps even the survival – of the biopharma industry is to excel at risk management. We are in an inherently risky business, where there are thousands of
Great example of how care is moving closer to the patient: NorthShore Betting on POC MDx Platform to Compete with Urgent Care Centers https://t.co/30MxOdiwBH
Another great example of efforts to deliver "sample to answer" workflow
Fluidigm, GenomOncology Partner to Create Integrated Workflow for Immuno-Oncology Research https://t.co/NckOTfFatP
Biocartis, Wondfo Announce Chinese Joint Venture https://t.co/lEyWmgT4BA
Biocartis Licenses EGFR Ectodomain Mutations https://t.co/TeRmS5g7ST
Roche's CEO of Diagnostics division bids adieu https://t.co/WmaoyxCcmS $RHHBY
New mRNA Cancer Drivers Revealed in Chronic Lymphocytic Leukemia https://t.co/yq9mwTkCRV
Illumina Receives Approval of MiSeq™Dx System in China - https://t.co/fc3YFPLJkQ
Good example of how to leverage a great commercial team to increase adoption of a great test. Congrats @exactsciences and @pfizer.
Exact Sciences, Pfizer to Comarket Cologuard https://t.co/ADVzk8x7kp
A test that tracks ctDNA levels can predict how patients with #DLBCL will respond to therapy within days of starting treatment https://t.co/1VCtXzBiO3 via @AJMC_Journal
@jajezmaz @EricTopol @DReuland @NPR @gordonmara1 And it will get more difficult to counsel as tests become more comprehensive. One example is molecular diagnostics, where panels are getting bigger. Patients sometimes think "more is better" but regret it once they get the results.
"It is incredibly exciting to study life’s blueprint during a time when it is within our grasp to understand what it really means." Great piece by @annewoj23 on what makes us human. The Codes That Bind Us, and Set Us Apart https://t.co/xkGlBOAFLN